US, EU, and Japanese Regulatory Guidelines for Development of Drugs for Treatment of Alzheimer’s Disease: Implications for Global Drug Development

Abstract

Drug development guidelines from regulatory authorities provide important information to sponsors on requirements for clinical evidence needed to support approval of new drugs. In the field of Alzheimer’s disease (AD), recently published guidelines are available from EU, US, and Japanese regulatory authorities. In this review, these three guidelines are compared and discussed with emphasis on the recommendations provided for demonstration of efficacy in pivotal clinical trials conducted in predementia stages of AD. Similarities and differences are highlighted, and impact for global drug development is discussed in the context of the new International Conference on Harmonization E17 guideline on multiregional clinical trials. The AD field is characterized by significant challenges as, to date, no drug approval precedence exists in predementia AD despite numerous and ambitious efforts to slow the progression of the disease by pharmacologic intervention. Despite these uncertainties regulatory authorities across regions have blazed a trail for proactive multistakeholder collaboration, involvement, and continuous dialogue, setting a positive example on how to foster a supportive environment for development of new and meaningful treatments for patients with AD globally.

Glaucoma Is Not Associated With Alzheimer's Disease or Dementia: A Meta-Analysis of Cohort Studies

“…Currently, Alzheimer's disease (AD) has become the most common cause of dementia for global population, which has significantly impaired the activities of daily living as well as the quality of life in these patients (1,2). Despite of continuous efforts in the development of novel treatments, therapeutic strategies for patients with AD, as well as those with dementia of other causes, remain limited, and the prognosis of patients with AD are still poor (3)(4)(5). With the accelerated aging process of global population, early identification of populations that are of higher risk for AD and dementia is important for the prevention of the diseases (6)(7)(8).…”

Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations

“…To date, no specific DLB outcome measures have been validated for use in clinical trials, which have typically relied on scales developed for AD and PD [ 5 ] (Table 1 ). Previously, regulatory authorities have emphasized the need for outcome measures that address functional, cognitive, and global domains in AD, but guidance is lacking in DLB [ 6 – 8 ].…”

Toward 3D‐Bioprinted Models of the Liver to Boost Drug Development

“…This procedure ensures the safety and efficacy of the new API, while assessing improvements related to the risk-benefit ratio of already established treatments. [1,2] The biggest liability of the whole process resides in the enormous amount of resources necessary to sustain the investment: a successful drug development has an average duration of approximatively 12 years and requires an average overall expenditure of ≈2 billion dollars. [3] Additionally, drug development is affected by an extremely low success rate, and only 0.01% -0.02% of the APIs entering the pipeline succeed in reaching the market.…”